Background: Oral squamous cell carcinoma (OSCC) is associated with high rates of recurrence and mortality. Although several well-known markers correlated with poor metastasis/prognosis in OSCC patients was reported, the molecular mechanisms of OSCC development are still not clear. Here, we explored angiotensin II type I receptor (AT1R) and itselicited signaling pathway participates in the metastatic progression of OSCC. Materials and Methods: The semi-quantitative-RT-PCR, Q-RT-PCR, western blot, and IHC approaches were used to evaluate the mRNA/protein expressions of AT1R in paired OSCC specimens. Immunohistochemical (IHC) staining of AT1R expression with clinic-patholgic characteristics was examined using univariate and multivariate analyses. Human oral cancer cell lines with overexpressing-AT1R or AT1R-mediated siRNAs were generated by transfection. Transwell chamber, wound healing, western blot, pharmacological inhibitors, and immunohistochemical assays were done to evaluate the signaling pathways that were involved. Results: We created a bioinformatics scheme consisting of integrating two gene expression profile datasets, including unpairwise OSCC, and secondary metastatic tumors vs. benign tumors. Among the novel targets identified, AT1R was upregulated in OSCC tissues and was associated with cancer metastasis. Furthermore, we employed two co-expression strategies to identify in which pathway AT1R was involved. By semi-quantitative-RT-PCR, Q-RT-PCR, Western blot and IHC approaches, we found that AT1R was not only an indicator of poor survival, but also exhibits positive correlations with MCP-1 expression in OSCC specimens. In vitro study, AT1R-overexpressing transfectants could increase the motility of cells via upregulation MCP-1 expression. Conversely, the motility of oral cancer cells could be suppressed by knock-down endogenous AT1R. These data indicated that AT1R promotes oral cancer metastasis via MCP-1 pathway. Conclusions: These finding suggested that AT1R is not only an important prognostic factor but also a new therapeutic target in the MCP-1 pathway for OSCC treatment.
